Results 51 to 60 of about 137,002 (346)

Insulin-like growth factor-1 is a negative modulator of glucagon secretion [PDF]

, 2017
Glucagon secretion involves a combination of paracrine, autocrine, hormonal, and autonomic neural mechanisms. Type 2 diabetes often presents impaired glucagon suppression by insulin and glucose.
Andreozzi, F, Di Fatta, C, Fuoco, A, Mancuso, E, Mannino, Gc, Sesti, G, Spiga, R   +6 more
core   +1 more source

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.

PLoS ONE, 2015
AimsTo determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.MethodsElectronic searches were conducted for ...
Jessica E Potts, Laura J Gray, Emer M Brady, Kamlesh Khunti, Melanie J Davies, Danielle H Bodicoat   +5 more
doaj   +1 more source

Use of glucagon-like peptide-1 receptor agonists in eating disorder populations.

International Journal of Eating Disorders, 2023
Glucagon-like peptide-1 receptor agonists (GLP-1As) are being used as approved or off-label treatments for weight loss. As such, there has been increasing concern about the potential for GLP-1As to impact eating disorder (ED) symptomatology. This article
Sara Bartel, Susan L. McElroy, Danielle Levangie, Aaron R Keshen   +3 more
semanticscholar   +1 more source

Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure.

Journal of Clinical Endocrinology and Metabolism, 2023
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have been used to reduce body weight in overweight or people with obesity and to improve glycemic control and cardiovascular outcomes among people with type 2 diabetes (T2D) and a high cardiovascular ...
J. P. Ferreira, Abhinav Sharma, J. Butler, M. Packer, F. Zannad, F. Vasques-Nóvoa, A. Leite-Moreira, J. Neves   +7 more
semanticscholar   +1 more source

Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy. [PDF]

, 2018
Class B peptide hormone GPCRs are targets for the treatment of major chronic disease. Peptide ligands of these receptors display biased agonism and this may provide future therapeutic advantage.
Andreassen, Arthur Christopoulos, Baldwin, Barwell, Belcheva, Berendsen, Black, Booe, Caroline A. Hick, Christopher A. Reynolds, Christopoulos, Christopoulos, Cosman, Dal Maso, de Graaf, Debbie L. Hay, Dehua Yang, Denise Wootten, Doerr, Dolinsky, Dong, Dong, Emma Dal Maso, Epand, Essmann, Eswar, Feyen, Furness, Gingell, Giuseppe Deganutti, Hamelryck, Harikumar, Harvey, Hay, Hilton, Huang, Humphrey, Johansson, Jorgensen, Koole, Koole, Krautler, Kuestner, Kuwasako, Kuwasako, Langston, Li, Liang, Lomize, Loncharich, Ming-Wei Wang, Minhas, Morfis, Orlowski, Patrick M. Sexton, Poyner, Sebastian G.B. Furness, Sommer, Udawela, Udawela, Vi Pham, Watkins, Weaver, Weston, Weston, Woolley, Woolley, Wootten, Wootten, Yue Zhu, Zhang   +70 more
core   +1 more source

Characterization of glucagon-like peptide-1 receptor-binding determinants [PDF]

Journal of Molecular Endocrinology, 2000
Glucagon-like peptide 1 (GLP-1) is a potent insulinotropic hormone currently under study as a therapeutic agent for type 2 diabetes. Since an understanding of the molecular mechanisms leading to high-affinity receptor (R) binding and activation may facilitate the development of more potent GLP-1R agonists, we have localized specific regions of GLP-1R ...
Q, Xiao, W, Jeng, M B, Wheeler
openaire   +2 more sources

Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement

Anaesthesia
Glucagon‐like peptide‐1 receptor agonists, dual glucose‐dependent insulinotropic peptide receptor agonists and sodium‐glucose cotransporter‐2 inhibitors are used increasingly in patients receiving peri‐operative care.
K. El-Boghdadly, J. Dhesi, Philippa Fabb, N. Levy, D. N. Lobo, A. McKechnie, Omar Mustafa, P. Newland-Jones, Anil Patel, D. Pournaras, Ken Clare, K. Dhatariya   +11 more
semanticscholar   +1 more source

Cerebral glucagon‐like peptide‐1 receptor activation alleviates traumatic brain injury by glymphatic system regulation in mice

CNS Neuroscience & Therapeutics, 2023
We aimed to assess the effects of cerebral glucagon‐like peptide‐1 receptor (GLP‐1R) activation on the glymphatic system and whether this effect was therapeutic for traumatic brain injury (TBI).
Chuanxiang Lv, Shuai Han, Z. Sha, Mingqi Liu, Shiying Dong, Chunyun Zhang, Zean Li, Kang Zhang, Shouyong Lu, Zhiyan Xu, L. Bie, Rongcai Jiang   +11 more
semanticscholar   +1 more source

The role of ECL2 in CGRP receptor activation: a combined modelling and experimental approach [PDF]

, 2013
The calcitonin gene-related peptide (CGRP) receptor is a complex of a calcitonin receptor-like receptor (CLR), which is a family B G-protein-coupled receptor (GPCR) and receptor activity modifying protein 1.
Alex C. Conner, Barwell J, Bruck Taddese, Christopher A. Reynolds, Conner AC, David R. Poyner, Debbie L. Hay, Harriet A. Watkins, James Barwell, Kevin J. Smith, Michael. J. Woolley, Urano D, Watkins HA, Z. Gamze Karakullukcu   +13 more
core   +2 more sources

Topical administration of GLP-1 eyedrops improves retinal ganglion cell function by facilitating presynaptic GABA release in early experimental diabetes

Neural Regeneration Research
Diabetic retinopathy is a prominent cause of blindness in adults, with early retinal ganglion cell loss contributing to visual dysfunction or blindness.
Yu-Qi Shao, Yong-Chen Wang, Lu Wang, Hang-Ze Ruan, Yun-Feng Liu, Ti-Hui Zhang, Shi-Jun Weng, Xiong-Li Yang, Yong-Mei Zhong   +8 more
doaj   +1 more source